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Introduction
So far, the effectiveness of symptomatic-based treatments 
for osteoarthritis (OA) is only small to moderate [1]. 
Efforts to develop disease-modifying drugs have not yet 
succeeded in diminishing symptomatic OA [2]. Given the 
wide range of available treatments in OA and their small 
to moderate effectiveness, better-targeted treatment is 
desirable.
Treatment guidelines for OA have stressed the need for 
research on clinical predictors of response to different 
treatments [3,4]. For example, the OA guideline of the 
Royal College of Physicians specifically mentions the 
complexity of OA in terms of pain and range of structural 
pathology, that few useful subclassifications of OA exist 
with respect to targeted treatment, and that it is unclear 
in which way co-morbidity in patients with OA influences 
treatment outcome [4].
Rothwell [5] identified several situations where a search 
for clinically important heterogeneity of treatment effects 
should be considered: first, in case multiple pathologies 
underlie a clinical syndrome; and second, in diseases with 
different severity and/or at different stages, or where co-
morbidity is frequently present. Both situations apply to 
OA patients; however, there is hardly any agreement 
about the classification of such OA subgroups.
Moreover, identifying clinical predictors of response to 
treatment is not simple. It is essential to use the correct 
methodology to identify such subgroups in order to avoid 
that some patients are erroneously deprived of certain 
treatments, or are erroneously assumed to have an 
(better) effect from such treatment. Therefore, this over-
view will discuss methodology of identifying clinical 
predic tors of response to different treatments, and pro-
pose the main OA subpopulations and give examples of 
how specific treatment effects in these subpopulations 
have been assessed.
Methods
This overview is based on a pragmatic search of the 
litera ture. In order to discuss the methodology, we 
searched in the Medline library for articles on the subject 
‘subgroup analysis’ in combination with ‘treatment’ and 
‘methodology’; a short overview of the main methods 
found and their implications are discussed, and summar-
ized in Table 1.
In order to give a classification of OA subpopulations, 
we searched the Medline library for articles on the com-
bination of ‘osteoarthritis’ and [phenotyp* OR subgroup* 
OR subpopulation] and [treatment* OR therapy OR 
intervention*]. Subgroups mentioned in the abstracts 
were classified under the subheadings phenotypes, struc-
tural and symptomatic stage, co-morbidity, and patient 
characteristics. Finally, we searched for more detailed 
information on these (kind of ) subpopulations and for 
examples of subgroup analysis with respect to treatment 
effects. Atrophic hip OA and genotypes were not found 
but are added, and briefly discussed. The main categories 
are summarized in Table 2.
Methodology in testing for subgroup effects of 
treatment
Subgroup-specific trials are obvious for the different OA 
joint groups, and for treatment specifically aimed at 
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certain OA subgroups, such as osteotomy for uni com-
part ment malaligned knee OA. However, to design such 
trials for every suspected subgroup for the available treat-
ments would take many years of research, and resources. 
Therefore, subgroup analyses or treatment response 
analyses within trials are undertaken.
Prognostic factors
A first issue to be addressed in subgroup analysis is the 
difference between the subgroup factor as a prognostic 
factor and as an effect modifier of treatment response. 
Single arm trials (or assessing predictors of response in 
only the active treatment group) identify prognostic 
factors and might wrongly suggest that the effect of 
treatment is greater in certain subgroups than in others 
[6]. To be identified as a subgroup that shows a different 
effect of treatment compared with another subgroup, the 
subgroup factor should be identified as an effect modifier. 
This means that the treatment interacts with the 
subgroup factor with respect to treatment outcome, 
showing another difference in outcome (effect) between 
treatment A and B in the specific subgroup. Conse-
quently, for such analyses a control group is needed.
Post hoc testing versus predefined testing
A frequently used method to identify subgroups with 
respect to effect of treatment is a post hoc analysis. The 
main analyses for effect of treatment in a two-arm trial 
are repeated in certain subgroups and tested for signi-
ficance of effect. However, this kind of analysis includes a 
high risk of false results; type I as well as type II errors 
[7,8]. Post hoc tests should therefore be regarded as un-
reliable unless they can be replicated [5].
As outlined by the CONSORT statement, reporting on 
subgroup effects in trials should only be done when the 
subgroup to be tested is predefined in the protocol, and 
the number of subgroups to be tested should be limited to 
the absolute minimum. The subgroups should be based on 
previous explorative research or on theoretical con sider-
ations, and the direction of the effects should be stated [5]. 
To anticipate equal distribution of the main prog nostic 
variables over the treatment arms in the sub groups, 
stratification of randomisation by the subgroup factor is 
advisable. In a predefined trial with subgroup testing the 
trial should be powered such that the expected effect, if 
present, should be detected in the smallest subgroup.
Subgroup-treatment interaction effect
A methodologically robust method is to test for a subgroup-
treatment interaction effect. Such analyses assess the 
statistical significance of the difference in effect between 
subgroups [7] by simply testing for a difference in treat-
ment effects making use of a standard normal approxi-
mation, or by including interaction terms in a regression 
model. Assessing interaction carries a much smaller risk 
of false-positive results. This kind of analysis will only 
show a positive result for interaction when the subgroup-
treatment interaction is very strong, or when the trial is 
Table 1. Key issues when assessing subgroup treatment effects
Prognostic factors are not necessarily treatment effect modifiers 
Post hoc subgroup effects in trials should be regarded as unreliable unless they can be replicated in dedicated trials or meta-analyses
When subgroup analysis is predefined in a trial, randomisation should be stratified by subgroup and the power should be adjusted to the smallest subgroup 
Testing for interaction effects in trials is more robust than subgroup analysis, but needs a well-powered study depending on the expected size of the interaction 
effect 
The number of subgroups should be limited to a minimum to avoid multiple testing
Combining trials for meta-analysis has the potential to search for subgroup effects. For reliable subgroup meta-analysis, individual trials have to supply 
subgroup effects and use stratified treatment randomization by subgroup, or supply the distribution of prognostic variables over the treatment arms in the 
subgroup 
Meta-analysis using individual patient data is a powerful method and the gold standard for assessing subgroup-treatment interaction effects
Table 2. Suggested main subgroups of OA in clinical 
research
OA phenotypes
 Joint site/joint compartment
 Localized or generalized osteoarthritis
 Structural osteoarthritis subtypes
 Pain phenotypes
Structural or symptomatic stage
 Pain severity
 Restricted motion 
 Radiographic severity 
 Effusion/synovitis 
 Bone marrow lesions
Co-morbidity
 Obesity
 Cardiovascular disease
 Chronic obstructive pulmonary disease
 Depression
Personal factors
 Gender
 Age
 Treatment preference
 Psychosocial factors
Bierma-Zeinstra and Verhagen Arthritis Research & Therapy 2011, 13:213 
http://arthritis-research.com/content/13/2/213
Page 2 of 9
powered to show such a result. In a trial speci fi cally 
designed to detect the supposed subgroup-treat ment inter-
actions, the sample size should be inflated fourfold when 
the interaction effect is equal to the overall treatment 
effect. When the interaction effect is only half of the overall 
treatment effect, the inflation factor is already 16 [8].
Meta-analysis of randomised controlled trials
A solution might be found in meta-analyses. Meta-
regression, one of the methods used, aims to relate the 
treatment effect recorded in the different trials to the 
characteristics of those trials in which the study is the 
unit of analysis. Even if appropriate statistical methods 
are used, relations with averages of the patients’ charac-
teristics in the trials are potentially misleading [9], due to 
confounding, unequal distributions, or to lack of power. 
Another method, meta-analysis dedicated to certain 
subgroups, might be possible when subgroup effects are 
reported, or when data on the subgroup effects can be 
retrieved from the authors. For a valid interpretation of 
these results, a stratified randomisation by subgroup 
factor in the individual trials is needed, or information on 
the distribution of prognostic variables over the treat-
ment arms in the subgroup should be supplied.
Meta-analysis with individual patient data
The third method, a meta-analysis for quantifying inter-
action effects using individual patient data (IPD), might 
overcome the power problem in individual trials and 
meta-regression analysis. A meta-analysis in which re-
analysis of all IPD can be accomplished is widely con-
sidered to be the gold standard. Authors of the included 
trials can be requested to make available their IPD, and/or 
well-designed collaborative projects can be initiated. In a 
meta-analysis using IPD, in which the data of several trials 
are pooled, the interaction effects between sub groups and 
treatment can be reliably assessed and poten tial 
confounders can be adjusted for [10]. Essential for such an 
analysis is that the baseline data with respect to defining 
subgroups and confounders are obtained in similar ways
Osteoarthritis subpopulations
Phenotypes
The historical classification of OA in primary and secon dary 
OA has been abandoned because OA is always secondary to 
something, and usually to a combination of factors [11]. 
Still, a way to define distinct phenotypes of OA could be 
based on the main risk factors and etiological factors [12]. 
Phenotypes can also be based on structural appearances, 
localization, site of manifestation, and on pain types.
Joint site
The different joint groups are generally seen as distinct 
phenotypes. For example, knee, hand, hip, and spine OA 
have different risk factors [13-15], and inheritance factors 
might be linked to joint-specific genes [16]. Even within 
these localizations there are distinct differences between, 
for example, localized thumb OA and nodal inter phalan-
geal hand OA [17,18], and between patellofemoral OA 
only and multi-compartment knee OA [19,20]. In addi-
tion, the different joint sites can have different structural 
and symptomatic appearances [21]. In spinal OA, specific 
neurological symptoms like neurogenic claudication, 
numbness, tingling, or weakness can be present due to 
lumbar spinal stenosis [22]. Whether or not treatment 
effects are expected to differ between these specific joint 
sites might depend on the kind of treatment.
Examples
The inflammatory component [21] or type of pain [23] 
might differ between hip OA and knee OA. Indeed, one 
study reported a higher effectiveness of oral nonsteroidal 
anti-inflammatory drugs (NSAIDs) in knee than in hip OA 
based on a re-analysis of a large trial comparing NSAIDs 
to placebo in patients with hip or knee OA [24]. However, 
the authors compared the before and after effects in the 
NSAID group between hip and knee patients, and not the 
in-between effects of NSAIDs versus placebo between hip 
and knee patients. If the placebo effect is also stronger in 
knee OA patients, there may not be greater effectiveness of 
NSAIDs in knee OA. In two meta-analyses combining two 
and three studies, respectively, the difference in the effect 
of NSAIDs versus placebo between hip and knee OA was 
formally evaluated for interaction effects in a meta-analysis 
with IPD. The authors could not show better effectiveness 
of NSAIDs in knee OA patients than in hip OA patients 
[25,26]. However, the selected studies in these two meta-
analyses included patients with increased pain following a 
wash-out period after NSAIDs (known as the flare design); 
in this way only potential responders were included and a 
difference in effect may no longer be expected.
It was not known whether the positive effects of exer cise 
for knee OA could be extrapolated to hip OA because 
exercise trials mostly included knee OA patients. In the 
trials combining knee and hip OA, the subgroups with 
hip OA were often too small for reliable subgroup 
analysis. Recently, Hernandez-Molina and colleagues [27] 
retrieved data from subgroups with hip OA in exercise 
trials that included both patients with hip OA and those 
with knee OA. With this meta-analysis in a site-specific 
subgroup the authors could confirm the effectiveness of 
exercise therapy in hip OA.
Generalized versus local osteoarthritis
The concept of generalized OA has been widely accepted 
[12]. Meta-analysis of genome-wide association studies 
confirmed that at least one allele is linked to a more 
systemic initiation of OA [28,29]. More rare forms of 
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early onset familial and progressive generalized OA have 
been linked to specific mutations [30]. Systemic acting 
treat ments might be more efficacious in a joint that is 
part of a generalized OA than in a joint-specific local OA 
where biomechanical factors may largely contribute to 
the disease. In addition, a systematic review showed that 
knee OA as part of generalized OA showed faster pro-
gression than local knee OA [31]. Many different defini-
tions for generalized OA have been used. Based on 
formal cluster analysis in more than a thousand OA 
patients, Dougados and colleagues [32] suggested that 
generalized OA should be defined as the presence of 
bilateral involvement of the fingers, or involvement of 
spine and both tibiofemoral joints. However, so far there 
is no agreed definition for generalized OA.
Examples
Rozendaal and colleagues [33] defined beforehand a 
subgroup analysis in patients with OA at more joint sites 
than the hip alone, in a trial assessing the effectiveness of 
glucosamine sulphate in patients with hip OA. The trial 
was also powered to assess symptomatic effects in the 
subgroups, and used a stratified treatment randomization 
for the subgroup generalized OA. The authors did not 
show any effect in this subgroup, but the effect was also 
absent in the total group.
Structural osteoarthritis subtypes
Whether or not atrophic versus hypertrophic OA, erosive 
versus non-erosive, and concurrent chondrocalcinosis 
should be seen as distinct etiological phenotypes or as a 
continuum of severity, or as being influenced by existing 
co-factors, is not yet entirely clear.
Atrophic osteoarthritis
OA can be classified as hypertrophic or atrophic accord-
ing to the presence or absence of osteophytes. A syste-
matic review showed strong evidence that the atrophic 
form demonstrates a faster progression of joint space 
narrowing than in hypertrophic OA [34]. Conrozier and 
colleagues [35] suggested that atrophic hip OA might be 
due to a relative deficiency in the synthesis of type II 
collagen, which is needed for enchondral ossification in 
the formation of osteophytes.
Erosive osteoarthritis
Erosive OA appears to be a specific subgroup of hand OA 
with worse clinical and structural outcomes. The 
ESCISIT task force [36] postulated that erosive hand OA 
targets interphalangial joints in the hand and shows 
radiographic subchondral erosion, which may progress to 
marked bone and cartilage attrition, instability and bony 
ankylosis. This kind of hand OA should possibly be 
treated differently because of the major inflammatory 
component in erosive hand OA. However, to date, only a 
few small pilot studies have specifically targeted erosive 
hand OA [37].
Chondrocalcinosis
Large calcium-containing crystal deposits in the joint 
can be detected radiographically and is called 
chondro calcinosis (CC). This is seen in 19% of end-
stage knee OA, and in 10% of end-stage hip OA [38]. 
There is some evidence that these calcium 
pyrophosphate crystals are biologically active particles 
that develop in the setting of cartilage damage, but 
also contribute to the osteo arthritis process [39]. 
Some studies suggest that OA with CC may differ 
from OA without CC in showing more osteo phy tosis 
and more inflammatory features [40], but whether or 
not the presence of CC might interact with various 
forms of treatment is not yet known. A recent study 
showed that CC is not associated with worsening of 
OA as defined by the progression on MRI [41].
Biomechanical deviations
Biomechanical deviations in the joint are known to be a 
risk factor for OA. A detrimental biomechanical influ-
ence in mal-aligned varus knees, due to the increased 
adduction moment in the knee, is widely recognized with 
respect to both initiation and progression of OA [42,43]. 
Femoral head abnormalities (for example, slipped 
femoral capital epiphysis) are well-known risk factors for 
hip OA [44]. Major dysplasia of the hip results in early 
onset of hip OA with fast progression; however, minor 
dysplasia is also a risk factor for hip OA [45], and hip OA 
with supero-lateral migration of the femoral head shows 
faster progression [34].
Kinematics in a joint might also undergo 
unfavourable change due to joint laxity and 
neuromuscular defici en cies. Overall, mechanical 
abnormalities in a joint are impor tant risk factors for 
OA, but mechanical abnor malities may also worsen 
(or be the result of ) an osteo arthritic process and 
become an important prognostic factor.
Injured joints
Local joint injury, and especially meniscal injury or 
meniscal ectomy, is widely recognized as being associated 
with the development of knee OA [46]. Apart from 
mechanical change in the knee due to these lesions, it is 
suggested that the biology in the knee has already 
changed in the first weeks after the acute injury; 
inflammatory processes in the initial phase are suggested 
to induce proteoglycan loss followed by subsequent 
collagen loss [47]. Both pathways might be involved in 
the initiation of post-traumatic OA with implications for 
possible preventive treatments.
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Examples
Lim and colleagues [48] performed a trial in which they 
included both mal-aligned and neutral positioned knee 
OA patients to assess the effect of quadriceps-strengthen-
ing exercises versus control treatment. Based on previous 
research, due to an increase of quadriceps strength they 
expected progression of the adduction moment in the 
mal-aligned group. They powered the trial on interaction 
between treatment and mal-alignment, but on formal 
testing found no such interaction effect between 
treatment and mal-alignment with respect to their 
primary outcome (adduction moment). However, they 
did find such an effect with repeated testing in one of the 
other five outcomes, indicating less pain relief of exercises 
in mal-aligned knees than in neutral knees. Given the 
reported significance for the interaction effect (P < 
0.001), the subgroup with varus alignment seems to need 
another kind of (exercise) treatment.
Pain phenotypes
Pain in OA differs between and within patients. At 
present there are more or less consistent reports on an 
association between OA pain and the presence of joint 
effusion, or subchondral bone lesions [49]. Other sug ges-
ted causes of pain in OA are bone attrition [50], neuro-
vascular invasion at the osteochondral junction [51], and 
ligament and tendon pathology [52]. How and whether 
these different sources of pain are reflected in different 
pain phenotypes is not well known. Night pain, pain at 
rest, and pain under load are the usual pain phenotypes 
mentioned in OA. In qualitative research, Hawker and 
colleagues [23] identified two main types of pain in 
people with OA of the knee and hip; a fairly constant (not 
disturbing) background pain, and a less frequent but 
more intense and often unpredictable pain.
In addition, different pain mechanisms in OA can exist. 
Besides the nociceptive pain, neuropathic pain might 
develop, for which different screenings tools are available 
[53]. Central sensitization can also be present in chronic 
pain. Although the traditional assessment of central sensi-
ti zation is complex, Nijs and colleagues [54] pro posed a 
more simple assessment to be used in clinical practice. 
These different pain phenotypes in OA can be of impor-
tance to target pain treatment, but at present very little OA 
intervention research in this direction has been done.
Genotypes
Osteoarthritis genotypes
So far, genotyping of OA has aimed to identify pathways 
in OA and find new targets for treatment. However, in 
future studies, combinations of genetic markers might 
also predict the risk for OA and identify certain sub-
groups with an increased risk for OA, identify subgroups 
of OA patients with fast progression, or identify OA 
patients susceptible for aseptic loosening of a prosthesis 
[55]. As yet, OA genotyping has not found any such 
clinical application.
Pain genotypes
A topic of increasing interest in recent OA research is the 
genetic variation in oa patients with respect to sensitivity 
for pain; a variation that might indicate a different need 
of pain management. One example is the catechol-O-
methyltransferase polymorphism in which the sensitivity 
for pain is increased [56,57]. Also, increasing data are 
available regarding several polymorphisms that influence 
the analgesic efficacy of nsaids, tramadol, codeine, and 
tryglyceric antidepressants, all with respect to drug meta-
bo lism [58]. More research in this area is needed, but will 
probably focus on pain syndromes in general rather than 
specifically on OA pain.
Structural or symptomatic stage of osteoarthritis
Knowing that OA is a progressive disease, it is important 
to establish at what stage of the disease certain treatment 
will be most effective. For example, for intended disease-
modifying drugs it is not expected that these will have 
any effect in a stage with pronounced structural changes 
or where apparent deleterious mechanical components 
are present [11].
Treatment effect might also depend on the severity of 
disease and specific symptoms. For example, the severity 
of pain, muscle weakness, restricted range of motion, and 
the presence or not of intra-articular joint effusion or 
synovitis in combination with a symptomatic flare might 
all influence the effects of different doses or types of pain 
medication, anti-inflammatory treatment, and exercise 
treatment or manual therapy.
Subchondral bone marrow lesions, an MRI sign that is 
seen in some OA patients and that can also disappear 
over time, represent foci of fibrosis and of osteonecrosis 
and bone remodelling [59]. Some of these are micro-
fractures of the trabecular bone at different stages of 
healing. These bone marrow lesions have been shown to 
correlate with the severity of pain and with progression 
of the disease [60]. Therefore, people with and without 
these signs might respond differently to certain treatment 
modalities.
Examples
Pincus and colleagues [61] evaluated the comparative 
pain reduction of NSAIDs and acetaminophen in patients 
with hip or knee OA, and assessed the interaction 
between type of medication and a pooled severity score, 
based on radiographic severity, symptomatic severity, 
and number of involved joints. Significant interaction 
effects were reported (without showing details), indicating 
similar effectiveness in the mildest group, but superior 
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effectiveness of NSAIDs in the more severe groups. The 
same was found when assessing the separate indicators 
for severity, except for the radiographic ones.
In clinical practice intra-articular corticosteroid injec-
tions are indicated in patients with knee effusion. 
However, there is limited evidence that such treatment 
might provide better effectiveness in those with effusions. 
Gaffney and colleagues [62] showed significantly better 
effect in the subgroup with clinical signs of effusion than 
in the subgroup without effusion. Another study showed 
no indication for better effects in the subgroup with signs 
of effusion [63], and a third study even found better 
results in the non-effusion group [64]. All studies 
assessed this effect only in the active treatment group 
and, therefore, only identified prognostic factors and not 
necessarily predictors of differences in effect.
Co-morbidity
Major well-known co-morbidities in OA patients are 
cardiovascular disease, obesity, and diabetes. However, 
sensory impairments, chronic obstructive pulmonary 
disease, and chronic low back pain are also frequent co-
morbidities in OA patients [65]. These diseases, their 
associated disabilities and/or medication may all interact 
with treatment for OA. For example, cardiovascular risk-
profile, renal function, glycaemic index history, and the 
use of anti-platelets or anti-hypertensive drugs will all 
influence the choice of whether to treat or not with a 
NSAID and what type to use [66]. Musculoskeletal co-
morbidity has repeatedly been shown to influence 
severity of symptoms [65,67,68]; coexistent lower back 
pain has also been shown to predict future pain and 
disability in people with hip OA [69]. The presence of 
coexistent lower back pain or buttock pain, often in 
combination with spine OA, is also a possible reason for 
continued pain at that location after total hip arthroplasty 
and dissatisfaction with the surgery [70].
Concurrent depressive complaints are frequently seen 
in OA patients [71] and may also interfere with treatment 
or treatment compliance. However, the ways in which co-
morbid conditions in people with OA influence outcomes 
of treatment have hardly been explored [4].
A high body mass index is a well-known risk factor for 
knee OA, and to a lesser degree for hip OA and hand OA, 
and probably acts through a change in load distribution 
in the knee [72], and systemic and local inflammatory 
cytokines [73,74] released by the adipose tissue. It also 
seems, however, to influence severity of symptoms; over-
weight people more often experience morning stiffness in 
the knee and have more severe knee pain than those who 
are not overweight but with the same degree of radio-
graphic severity [75]. Although weight loss is a main goal 
in overweight OA patients, their weight might also have 
implications for other OA treatments.
Patient characteristics
Gender, age, educational level, and psychosocial charac-
teristics might all influence the effect of treatment. Above 
the age of 50 years, the incidence of OA rises steeply in 
women but less so in men, suggesting an association with 
changes in female hormone levels during menopause. 
However, systematic reviews could not find clear 
evidence for the assumed association between OA and 
aspects concerning the fertile period and menopause; 
only some evidence of a protective effect of unopposed 
oestrogen use for hip OA was found [76,77]. Recently, it 
was found that symptomatic postmenopausal women 
clearly differ from those without vasomotor symptoms 
with respect to the risk for future cardiovascular disease 
[78]. This might also be the case with respect to OA. 
Whether or how female hormone levels or other female 
characteristics interact with different kinds of treatment 
is not yet known.
Depending on the type of intervention, one might 
consider the interaction of such characteristics with the 
treatment. For example, treatments that include a change 
of lifestyle, or behavioural treatment, might be highly 
dependent on intrinsic motivation, or on psychological 
factors, like coping style or level of locus of internal 
control [79]. Another well-known factor that influences 
treatment effect is the expectation the patient has about 
the treatment. A systematic review found that, in ran-
dom ised open-label trials (back pain trials), about 57% of 
patients had a treatment preference, and that the effect 
size increased by 0.162 in patients with a treatment 
preference that also received this treatment compared to 
the ‘indifferent’ patients [80].
Examples
Veenhof and colleagues [81] assessed which hip or knee 
OA patients benefit most from a specific treatment in a 
randomised controlled trial on behavioural graded 
activity therapy versus common exercise therapy. They 
tested for interaction effects in a multivariable model and 
found that patients with a relatively low level of physical 
functioning benefit more from behavioural therapy than 
from common exercise therapy. For a low level of internal 
locus of control the interaction with the kind of treatment 
was marginally significant.
Conclusions
Defining subgroups in OA remains difficult, especially 
because the etiopathogenesis of OA is not yet fully 
understood. It becomes even more complicated when the 
mechanism of action in treatments is not fully elucidated. 
In addition, several subgroups may well be derived from 
different dimensions of the disease and be treatment 
specific and will, therefore, overlap each other. Because of 
this, a mutually exclusive classification of subgroups with 
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respect to targeted treatment may not only be impossible 
to achieve, but may also not be desirable.
In addition, when defining subgroups in clinical 
research, one should keep in mind that the ultimate goal 
of identifying a subgroup that is responsive to a specific 
treatment is that clinicians can also identify these 
patients in practice. Should subgrouping become more 
costly, invasive or time consuming than the treatment 
itself, it will not be clinically applicable and may have 
only helped us to understand the mechanism of action of 
a specific type of treatment.
Because OA is a heterogeneous disease, identifying 
sub groups for treatments is probably one of the promis-
ing ways forward in clinical research. This can only be 
achieved when the correct methodology to identify such 
subgroups is used, and the frequently reported post hoc 
testing is only regarded as hypothesis generating.
International collaborative initiatives aiming to define 
the most promising treatment-specific subgroups are 
needed and consensus should be reached on the case 
definition of these subgroups. Such subgroup definitions 
can be used for predefined subgroup analysis or dedi-
cated trials, or for equal baseline measurement of these 
subgroup factors in trials to facilitate future meta-
analyses, as well as initiatives to combine IPD from 
several randomised controlled trials, all in order to 
generate appropriate recommendations for the effective 
treatment of various subgroups.
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